Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8 mg for visual impairment due to macular edema secondary to retinal vein occlusion (RVO) – marking the third indication nod in Japan for the high‑dose formulation and validating extended dosing intervals with patients receiving on average three fewer injections through week 64 vs. standard 2 mg dosing.
Regulatory Milestone
Item
Detail
Agency
MHLW (Ministry of Health, Labour and Welfare, Japan)
Product
Eylea HD (aflibercept) injection 8 mg
Companies
Bayer AG + Regeneron Pharmaceuticals, Inc.
New Indication
Macular edema secondary to RVO (branch, central, hemi‑retinal vein occlusion)
Approval Basis
Phase III QUASAR study
Japan Indication Count
Third (nAMD, DME, RVO)
Recent EU Approval
RVO indication approved (reference for Japan submission)
Clinical Evidence – QUASAR Phase III
Endpoint
Eylea HD 8 mg
Eylea 2 mg
Clinical Advantage
Visual Acuity Maintenance
Maintained
Maintained
Non‑inferior efficacy
Total Injections (Week 64)
8.5
11.7
3 fewer injections – reduced treatment burden
≥4‑Month Treatment Interval
>60% of patients
–
Extended dosing sustainability
5‑Month Interval Achievement
40% of patients
–
Maximum convenience segment
Dosing Regimen: Three initial monthly doses → extended interval maintenance
RVO Market Dynamics: Retinal vein occlusion affects ~1.5 million patients annually globally; macular edema leading cause of vision loss in RVO; anti‑VEGF standard of care with treatment burden (monthly injections) major compliance challenge; Eylea HD’s extended interval (Q4‑5 months vs. Q4‑8 weeks standard) addresses unmet need for reduced injection frequency.
Eylea HD Differentiation: 8 mg high‑dose formulation enables sustained VEGF suppression supporting extended intervals; 3 fewer injections over 64 weeks translates to ~25% reduction in treatment burden; 40% achieving 5‑month intervals positions for competitive advantage vs. Roche’s Vabysmo (faricimab, Q4‑16 weeks) and Novartis’s investigational high‑dose therapies.
Japan Market Strategy: Third indication approval validates MHLW confidence in Eylea HD safety/efficacy profile; RVO patient population (~50,000‑80,000 annually in Japan) adds ¥10‑15 billion incremental revenue potential (2026‑2028); physician preference for extended dosing in injection‑fatigued patients drives market share capture from standard‑dose Eylea and competitor products.
Bayer Ex‑US Commercial Execution: Bayer’s ophthalmology franchise strength (Europe, Asia‑Pacific, Latin America) leverages Eylea HD RVO approval for global rollout; 50/50 profit share with Regeneron maintains partnership alignment; EU + Japan + 60+ market approvals support US$800 million‑1.2 billion annual Eylea HD ex‑US peak sales (2028‑2030).
Competitive Response: Roche’s Vabysmo (faricimab) offers Q4‑16 week dosing but no 8 mg equivalent; Novartis high‑dose brolucizumab limited by safety concerns; Eylea HD’s proven safety profile + extended interval may defend market leadership against bispecific and next‑gen VEGF inhibitors; price premium for HD formulation (~10‑15% over 2 mg) justified by reduced injection burden.
Forward‑Looking Statements This brief contains forward‑looking statements regarding market expansion timelines, competitive positioning, and revenue projections for Eylea HD in RVO and other indications. Actual results may differ due to competitive dynamics with Vabysmo and emerging therapies, reimbursement negotiations in Japan and EU markets, and long‑term safety data requirements for high‑dose anti‑VEGF therapy.-Fineline Info & Tech
By Fineline Cube 